Free Trial
NASDAQ:PLUR

Pluri 2/11/2025 Earnings Report

Pluri logo
$4.51 -0.06 (-1.31%)
Closing price 03:53 PM Eastern
Extended Trading
$4.51 0.00 (0.00%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Pluri EPS Results

Actual EPS
-$0.53
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Pluri Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Pluri Announcement Details

Quarter
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Pluri Earnings Headlines

Pluri (NASDAQ:PLUR) Stock Price Up 0.2% - Should You Buy?
Pluri Inc. reschedules 2025 annual meeting
Shocking discovery could help you target payouts on weekends…
Since the pandemic, the average mortgage payment has jumped from $1,427 to $2,047. That's an extra $600 every single month just vanishing from people's pockets. Meanwhile, credit card debt is hitting record highs, and savings accounts are at their lowest since 2008. Most folks are left with two options… Get a second job... or work overtime on weekends. But what if there was a third option? I just uncovered a shocking anomaly in the options market that could change everything... One that lets you target extra cash on days when most people make nothing - weekends. Think what that could mean for your monthly budget...
See More Pluri Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Pluri? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Pluri and other key companies, straight to your email.

About Pluri

Pluri (NASDAQ:PLUR), a biotechnology company, engages in the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions. It operates in the field of regenerative medicine, food-tech, and biologics and focuses on establishing partnerships that leverage its 3D cell-based technology to additional industries that require mass cell production. The company's development pipeline includes PLX-PAD, is composed of maternal mesenchymal stromal cells originating from the placenta that is currently under phase III study for orthopedic, phase II study for COVID-19, and phase I/II clinical study for Steroid-Refractory cGVHD indications; and PLX-R18, is composed of fetal MSC like cells originating from the placenta that is currently under phase I study for HCT and pilot study for ARS indications. It is also involved in the development of modified PLX cells. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.

View Pluri Profile

More Earnings Resources from MarketBeat